← Search & browse all drugs
MUSCULO-SKELETAL SYSTEM › ANTIGOUT PREPARATIONS › ANTIGOUT PREPARATIONS › Preparations increasing uric acid excretion
probenecid
M04AB01
Adult Dosing
- Gouty arthritis/hyperuricemia: 250 mg twice daily for 1 week, then 500 mg twice daily; may increase by 500 mg every 1-2 weeks up to max 2 g/day as needed to maintain serum uric acid control
- Adjunct to penicillin/cephalosporin therapy: 500 mg four times daily
Pediatric Dosing
- Not recommended for children under 2 years of age
- Gouty arthritis (children >2 years): Initial 25 mg/kg (or 700 mg/m2) given in divided doses 4 times daily, then maintenance 40 mg/kg/day up to max 2 g/day
Indications
- Hyperuricemia associated with gout and gouty arthritis
- Prolongation of plasma levels of certain beta-lactam antibiotics (penicillins and cephalosporins)
Mechanism of Action
- Uricosuric agent that inhibits the renal tubular reabsorption of uric acid, thereby increasing urinary excretion of uric acid and lowering serum urate levels
- Competitively inhibits the renal tubular secretion of weak organic acids (e.g., penicillins, cephalosporins), thereby increasing and prolonging their serum concentrations
Contraindications
- Hypersensitivity to probenecid or any component of the product
- Known blood dyscrasias
- Uric acid kidney stones
- Initiation during an acute gouty attack
- Concurrent use with low-dose aspirin therapy (antagonizes uricosuric effect)
Adverse Reactions
- Headache
- Dizziness
- Nausea
- Vomiting
- Anorexia
- Gingival soreness
- Urine frequency
- Hypersensitivity reactions (rash, pruritus, fever, anaphylaxis)
- Hemolytic anemia (especially in G6PD deficiency)
- Aplastic anemia (rare)
- Nephrotic syndrome (rare)
Drug Interactions
- Salicylates/aspirin: Antagonize the uricosuric action of probenecid; concurrent use is avoided
- Methotrexate: Inhibits renal excretion of methotrexate, increasing risk of severe toxicity and myelosuppression
- NSAIDs: Probenecid may decrease the clearance of NSAIDs (e.g., indomethacin, naproxen), increasing their toxicity risk
- Sulfonylureas: Decreases clearance and enhances hypoglycemic effect of oral hypoglycemic agents
- Lorazepam: Inhibits glucuronidation and clearance, prolonging elimination half-life
Curated Content: Needs Vetting Before Put to Clinical Use